Posted by Michael Wonder on 30 Jul 2025
CDA issues positive reimbursement recommendation for Skyclarys (omaveloxolone), the only Health Canada approved treatment for managing Friedreich ataxia
29 July 2025 - Biogen Canada is pleased to announce a significant step forward for Canadians living with Friedreich ataxia, with the positive reimbursement recommendation by Canada's Drug Agency Canadian Drug Expert Committee for Skyclarys (omaveloxolone) as a treatment for patients 16 years of age and older who meet certain criteria.
This milestone brings Canadians outside Quebec affected by this rare neurodegenerative disease a step closer to accessing the only approved therapy for the condition.
